以色列 - 希伯来文 - Ministry of Health

novartis israel ltd - tisagenlecleucel - tisagenlecleucel

以色列 - 希伯来文 - Ministry of Health

bristol - myers squibb, israel - atazanavir as sulfate - קפסולות - atazanavir as sulfate 300 mg - atazanavir

以色列 - 希伯来文 - Ministry of Health

glaxo smith kline (israel) ltd - aciclovir - טבליה - aciclovir 400 mg - aciclovir - aciclovir - for the treatment of herpes simplex virus infections of the skin and mucous membranes including intial and recurrent genital herpes. for the suppression (prevention of recurrences) of recurrent herpes simplex infections in immune-competent patients. for the prophylaxis of herpes simplex infections in immune-compromised patients. for the treatment of herpes zoster infections . for the treatment of chickenpox.

以色列 - 希伯来文 - Ministry of Health

glaxo smith kline (israel) ltd - aciclovir - טבליה - aciclovir 200 mg - aciclovir - aciclovir - for the treatment of herpes simplex virus infections of the skin and mucous membranes including initial and recurrent genital herpes. for the suppression (prevention of recurrences) of recurrent herpes simplex infections in immune-competent patients. for the prophylaxis of herpes simplex infections in immune-compromised patients. for the treatment of herpes zoster infections . for the treatment of chickenpox.

以色列 - 希伯来文 - Ministry of Health

glaxo smith kline (israel) ltd - aciclovir - טבליות ניתנות לפיזור - aciclovir 800 mg - aciclovir - aciclovir - for the treatment of herpes simplex virus infections of the skin and mucous membranes including initial and recurrent genital herpes. for the suppression (prevention of recurrences) of recurrent herpes simplex infections in immune-competent patients. for the prophylaxis of herpes simplex infections in immune-compromised patients. for the treatment of herpes zoster infections . for the treatment of chickenpox in the following groups: 1. non-pregnant patients over 13 years-of-age who are otherwise healthy. 2. children over 12 months of age with a chronic cutaneous or pulmonary condition, or receiving long-term salicylate therapy. 3. children receiving short or intermittent courses of aerosolized corticosteroids.

以色列 - 希伯来文 - Ministry of Health

glaxo smith kline (israel) ltd - aciclovir - תרחיף - aciclovir 200 mg / 5 ml - aciclovir - aciclovir - zovirax oral presentations are indicated for the treatment of herpes simplex virus infections of the skin and mucous membranes including initial and recurrent genital herpes, for the suppression (prevention of recurrences) of recurrent herpes simplex infections in immune-competent patients, for the prophylaxis of herpes simplex infections in immune-compromised patients and for the treatment of herpes zoster (shingles) infections. studies have shown that early treatment of shingles with zovirax has a beneficial effect on pain and can reduce the incidence of post-herpetic neuralgia (zoster associated pain). zovirax oral presentations should be considered for the treatment of chickenpox in certain groups at increased risk of severe varicella or its complications. these groups are as follows: 1. non-pregnant patients over 13 years-of-age who are otherwise healthy. 2. children over 12 months of age with a chronic cutaneous or pulmonary condition, or receiving long-term salicylate therapy. 3. children receiving sho

以色列 - 希伯来文 - Ministry of Health

pfizer pharmaceuticals israel ltd - sirolimus - תמיסה (פומי) - sirolimus 1 mg/ml - sirolimus - sirolimus - rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. it is recommended that rapamune be used initially in combination with cyclosporine microemulsion and corticosteroids for 2 to 3 months. rapamune may be continued as maintenance therapy with corticosteroids only if cyclosporine can be progressively discontinued.

以色列 - 希伯来文 - Ministry of Health

cts chemical industries ltd - promethazine as hydrochloride 50.0 mg / 2 ml - solution for injection - promethazine - amelioration of allergic reactions to blood or plasma. in analphylaxis as an adjunct to adrenaline and other standard measures after the acute symptoms have been controlled. for other uncomplicated allergic conditions of the immedite type when oral therapy is impossible or contraindicated. preoperative, postoperative and obstetric (during lobour) sedation. prevention and control of nausea and vomiting associated with certain types of anaesthesia and surgery. for sedation and relief of apprehension and to induce light sleep from which the patient can be easily aroused. intravenously in special surgical situations, such as repeated bronchoscopy, opthalmic surgery and poor-risk patients with reduced amounts of meperidine or other narcotic analgesic as an adjunct to anaesthesia and analgesia.

以色列 - 希伯来文 - Ministry of Health

sanofi israel ltd - alemtuzumab - תרכיז להכנת תמיסה לאינפוזיה - alemtuzumab 12 mg / 1.2 ml - alemtuzumab

以色列 - 希伯来文 - Ministry of Health

novartis israel ltd - omalizumab - אבקה וממס להכנת תמיסה להזרקה - omalizumab 150 mg/dose - omalizumab - omalizumab - xolair is indicated for adults and adolescents (12 years of age and above) with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. xolair has been shown to decrease the incidence of asthma exacerbations in these patients. safety and efficacy have not been established in other allergic conditions.